Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Supplement—October 2025


SUPPLEMENT ISSUE
Supplement

Persistence of Symptoms among Commercially Insured Patients with Coccidioidomycosis, United States, 2017–2023

Ian Hennessee1Comments to Author , Samantha L. Williams, Kaitlin Benedict, Dallas J. Smith, George R. Thompson, and Mitsuru Toda
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (I. Hennessee, S.L. Williams, K. Benedict, D.J. Smith, M. Toda); University of California, Davis, Sacramento, California, USA (G.R. Thompson III)

Main Article

Figure 1

Period prevalence of selected coccidioidomycosis symptoms among commercially insured patients with coccidioidomycosis, United States, July 2017‒January 2023. Prevalence is shown for chest pain (A), chills (B), cough (C), dyspnea (D), erythema nodosum or multiforme (E), fatigue (F), fever (G), headache (H), hyperhidrosis (I), joint pain (J), weakness (K), and weight loss (L). The index period (0–29 days after index date) is shown with a dotted line. Data for myalgia are not shown because period prevalence was <1%. X-axis labels represent the beginning of 1-month follow-up periods relative to the index date (e.g., –6 refers to the period of 6–5 months before the index date). 

Figure 1. Period prevalence of selected coccidioidomycosis symptoms among commercially insured patients with coccidioidomycosis, United States, July 2017‒January 2023. Prevalence is shown for chest pain (A), chills (B), cough (C), dyspnea (D), erythema nodosum or multiforme (E), fatigue (F), fever (G), headache (H), hyperhidrosis (I), joint pain (J), weakness (K), and weight loss (L). The index period (0–29 days after index date) is shown with a dotted line. Data for myalgia are not shown because period prevalence was <1%. X-axis labels represent the beginning of 1-month follow-up periods relative to the index date (e.g., –6 refers to the period of 6–5 months before the index date). 

Main Article

1Current affiliation: The Carter Center, Atlanta, Georgia, USA

Page created: September 02, 2025
Page updated: November 14, 2025
Page reviewed: November 14, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external